Background: The clinicopathological significance of the mucinous subtype of colorectal cancer (CRC) remains controversial. As of today, none of the current guidelines differentiate treatment with respect to mucinous or nonmucinous cancer. Due to the lack of substantiated data, best treatment remains unclear and the mucinous subtype of CRC is usually treated along the lines of recommendations for adenocarcinoma of the colon. Methods: We investigated an East-Bavarian cohort of 8,758 patients with CRC. These included 613 (7.0%) patients with a mucinous subtype, who were analyzed for assessing their characteristics in clinical course and for evaluating the efficacy of common chemotherapy protocols. Results and Conclusion: Mucinous CRC was predominantly located in the right hemicolon; it was diagnosed at more advanced stages and occurred with preponderance in women. A higher rate of G3/4 grading was observed at diagnosis (all p < 0.001). An association of mucinous CRC with younger age at initial diagnosis, previously reported by other groups, could not be confirmed. Patients with mucinous stage IV colon cancer demonstrated poorer survival (p = 0.006). In contrast, no differences in survival were observed for specific stages I–III colon cancer. Stage-dependent analysis of rectal cancer stages I–IV also showed no differences in survival. However, univariable overall analysis resulted in significant poorer survival of mucinous compared to nonmucinous rectal cancer (p = 0.029). Also, combined analysis of all patients with mucinous CRC revealed poorer overall survival (OS) of these patients compared to nonmucinous CRC patients (median 48.4 vs. 60.2 months, p = 0.049) but not in multivariable analysis (p = 0.089). Chemotherapeutic treatment showed comparable efficacy regarding OS for mucinous and nonmucinous cancers in both an adjuvant and palliative setting for colon cancer patients (p values comparing mucinous and nonmucinous cancers < 0.001–0.005).

Journal Section:
Original Paper
Keywords:
Colon cancer, Chemotherapy, Colorectal cancer, Mucinous subtype
1.
Brenner H, Kloor M, Pox CP: Colorectal cancer. Lancet 2014; 383: 1490–1502.
[PubMed]
https://doi.org/10.1016/S0140-6736(13)61649-9
2.
van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RG, van den Broek CB, Brown G, Van Cutsem E, et al: EURECCA colorectal: multidisciplinary management: European consensus conference colon &amp;amp; rectum. Eur J Cancer 2014; 50: 1.e1–1.e34.
[PubMed]
https://doi.org/10.1016/j.ejca.2013.06.048
3.
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(suppl 3): iii1–iii9.
[PubMed]
https://doi.org/10.1093/annonc/mdu260
4.
http://www.nccn.org/patients/guidelines/colon/files/assets/common/downloads/files/colon.pdf.
5.
Hanski C: Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer 1995; 72: 1350–1356.
[PubMed]
6.
Zhang H, Evertsson S, Sun X: Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol 1999; 14: 1057–1061.
[PubMed]
7.
Kim DH, Kim JW, Cho JH, Baek SH, Kakar S, Kim GE, Sleisenger MH, Kim YS: Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol 2005; 27: 957–964.
[PubMed]
8.
Song GA, Deng G, Bell I, Kakar S, Sleisenger MH, Kim YS: Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol 2005; 26: 745–750.
[PubMed]
9.
Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright JB Jr, Ray JE: Mucinous carcinoma – just another colon cancer? Dis Colon Rectum 1993; 36: 49–54.
[PubMed]
https://doi.org/10.1007/BF02050301
10.
Nozoe T, Anai H, Nasu S, Sugimachi K: Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 2000; 75: 103–107.
[PubMed]
https://doi.org/10.1002/1096-9098(200010)75:2<103::AID-JSO6>3.0.CO;2-C
11.
Secco GB, Fardelli R, Campora E, Lapertosa G, Gentile R, Zoli S, Prior C: Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. Oncology 1994; 51: 30–34.
[PubMed]
https://doi.org/10.1159/000227306
12.
Consorti F, Lorenzotti A, Midiri G, Di Paola M: Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73: 70–74.
[PubMed]
https://doi.org/10.1002/(SICI)1096-9098(200002)73:2<70::AID-JSO3>3.0.CO;2-J
13.
Kanemitsu Y, Kato T, Hirai T, Yasui K, Morimoto T, Shimizu Y, Kodera Y, Yamamura Y: Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003; 46: 160–167.
[PubMed]
https://doi.org/10.1097/01.DCR.0000044721.76711.6D
14.
Papadopoulos VN, Michalopoulos A, Netta S, Basdanis G, Paramythiotis D, Zatagias A, Berovalis P, Harlaftis N: Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol 2004; 8(suppl 1): s123–s125.
[PubMed]
https://doi.org/10.1007/s10151-004-0131-z
15.
Du W, Mah JT, Lee J, Sankila R, Sankaranarayanan R, Chia KS: Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 2004; 47: 78–85.
[PubMed]
https://doi.org/10.1007/s10350-003-0014-9
16.
Maksimovic S: [Survival rates of patients with mucinous adenocarcinoma of the colorectum]. Med Arh 2007; 61: 26–29.
[PubMed]
17.
Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN, Chang GJ: Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 2012; 19: 2814–2821.
[PubMed]
https://doi.org/10.1245/s10434-012-2321-7
18.
Verhulst J, Ferdinande L, Demetter P, Ceelen W: Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol 2012; 65: 381–388.
[PubMed]
https://doi.org/10.1136/jclinpath-2011-200340
19.
Wu CS, Tung SY, Chen PC, Kuo YC: Clinicopathological study of colorectal mucinous carcinoma in Taiwan: a multivariate analysis. J Gastroenterol Hepatol 1996; 11: 77–81.
[PubMed]
https://doi.org/10.1111/j.1440-1746.1996.tb00014.x
20.
Lee CT, Huang YC, Hung LY, Chow NH, Su PF, Ho CL, Tsai HW, Chen YL, Lin SC, Lin BW, et al: Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival. Oncotarget 2017; 8: 35165–35175.
[PubMed]
https://doi.org/10.18632/oncotarget.16815
21.
Shia J, Schultz N, Kuk D, Vakiani E, Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR, et al: Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. Mod Pathol 2017; 30: 599–609.
[PubMed]
https://doi.org/10.1038/modpathol.2016.198
22.
Mekenkamp LJ, Heesterbeek KJ, Koopman M, Tol J, Teerenstra S, Venderbosch S, Punt CJ, Nagtegaal ID: Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012; 48: 501–509.
[PubMed]
https://doi.org/10.1016/j.ejca.2011.12.004
23.
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, et al: Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 2009; 100: 881–887.
[PubMed]
https://doi.org/10.1038/sj.bjc.6604955
24.
Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ: Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005; 16: 1305–1310.
[PubMed]
https://doi.org/10.1093/annonc/mdi244
25.
Maisano R, Azzarello D, Maisano M, Mafodda A, Bottari M, Egitto G, Nardi M: Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer. J Chemother 2012; 24: 212–216.
[PubMed]
https://doi.org/10.1179/1973947812Y.0000000013
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.